/wp-content/uploads/2021/10/logo_color.svg00david/wp-content/uploads/2021/10/logo_color.svgdavid2021-11-12 08:00:002021-11-12 08:02:30Glympse to Present Dataset Demonstrating Liquid Biopsy Approach to Predict NASH at AASLD’s The Liver Meeting
/wp-content/uploads/2021/10/logo_color.svg00david/wp-content/uploads/2021/10/logo_color.svgdavid2021-11-01 16:54:002021-11-03 09:55:43Glympse to Present Data from First Application of New Liquid Biopsy Diagnostic Platform at AASLD’s The Liver Meeting 2021
/wp-content/uploads/2021/10/logo_color.svg00raincastle/wp-content/uploads/2021/10/logo_color.svgraincastle2021-07-27 14:41:002021-10-27 14:46:53Glympse Bio Appoints Matthew T. Navarro, J.D., as Chief Financial Officer
/wp-content/uploads/2021/10/logo_color.svg00raincastle/wp-content/uploads/2021/10/logo_color.svgraincastle2021-02-02 14:47:002021-10-27 14:47:41Glympse Bio Names Jessica Atkinson Senior Vice President of Business Development
/wp-content/uploads/2021/10/logo_color.svg00raincastle/wp-content/uploads/2021/10/logo_color.svgraincastle2020-11-13 14:48:002021-10-27 14:49:05First-In-Human Data Supporting the Safety of Glympse Bio’s Biosensors are Presented at the AASLD 2020 Annual Meeting
/wp-content/uploads/2021/10/logo_color.svg00raincastle/wp-content/uploads/2021/10/logo_color.svgraincastle2020-11-10 14:50:002021-10-27 14:51:49Glympse Bio to Present Clinical Data at the AASLD 2020 Annual Meeting
/wp-content/uploads/2021/10/logo_color.svg00raincastle/wp-content/uploads/2021/10/logo_color.svgraincastle2020-07-15 14:55:002021-10-27 14:55:47Glympse Bio Announces $46.7 Million Series B Financing